Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 1/2006

01-03-2006 | Original Paper

Bosentan® inhibits tumor vascularization and bone metastasis in an immunocompetent skin-fold chamber model of breast carcinoma cell metastasis

Authors: Didier Dréau, Amel Karaa, Cathy Culberson, Heather Wyan, Iain H. McKillop, Mark G. Clemens

Published in: Clinical & Experimental Metastasis | Issue 1/2006

Login to get access
Metadata
Title
Bosentan® inhibits tumor vascularization and bone metastasis in an immunocompetent skin-fold chamber model of breast carcinoma cell metastasis
Authors
Didier Dréau
Amel Karaa
Cathy Culberson
Heather Wyan
Iain H. McKillop
Mark G. Clemens
Publication date
01-03-2006
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 1/2006
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-006-9016-z

Other articles of this Issue 1/2006

Clinical & Experimental Metastasis 1/2006 Go to the issue

Review Paper

Comprehensive Analysis of Recent Biochemical and Biologic Findings Regarding a Newly Discovered Protein-PELP1/MNAR

Original Paper

Tissue array-based expression of transglutaminase-2 in human breast and ovarian cancer

Original paper

The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice

Original Research

Clinical Evaluation of E-cadherin Expression and its Regulation Mechanism in Epithelial Ovarian Cancer

Original Paper

Hypoxia increases VEGF-A production by prostate cancer and bone marrow stromal cells and initiates paracrine activation of bone marrow endothelial cells

Original paper

Heparanase Expression and TrkC/p75NTR Ratios in Human Medulloblastoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits